This therapeutic is a engineered antibody primarily targeting MUC1, a transmembrane protein frequently amplified in various tumors, including breast carcinoma . Its mechanism of action involves binding to https://cantuzumab-anti-muc1-mab791940.blogdigy.com/cantuzumab-a-deep-dive-into-the-anti-muc1-antibody-67759180